Biogenesis and metabolism of Alzheimer’s disease Aβ amyloid peptides
Introduction
Alzheimer’s disease is the most common form of dementia and affects one in four individuals aged over 85. Post-mortem diagnosis includes major degeneration of the brain cortex with presence of amyloid as large extracellular plaques, perivascular deposits, and intra-neuronal fibrillary tangles. The amyloid or senile plaques are composed of Aβ peptides [94]. These peptides are proteolytically derived from a type 1 integral protein termed amyloid precursor protein (APP) [68] and contain part of the membrane-spanning domain. APP’s function remains poorly understood although it has been implicated with cell adhesion and neurite outgrowth. Whether Aβ production is physiologically important or simply represents a metabolic pathway of APP degradation is debatable [178] but increasing experimental evidence supports the amyloid cascade hypothesis [53]: accumulation and aggregation of Aβ is the primary cause of AD, inducing an inflammatory response followed by neuritic injury, hyperphosphorylation of tau protein and formation of fibrillary tangles, leading ultimately to neuronal dysfunction and cell death. Animal models which reproduce AD pathology and develop amyloid deposits show learning deficits reminiscent of those of humans affected with the disease [21]. Thus, prevention of Aβ production and accumulation is currently being evaluated as a potential therapeutic intervention for AD. We will review the current knowledge of the proteolytic processing of APP, that generates the Aβ peptides and of how these become metabolized and degraded (Fig. 1).
Section snippets
Aβ amyloid protein and Alzheimer’s disease
The presence of amyloid plaques and congophilic angiopathy in the brain cortex and hippocampus has for long been recognized as a major pathological feature of AD [2]. Isolation and chemical characterization of the amyloid plaques and vascular amyloid revealed the Aβ protein [52], [94] and led to cloning of the APP [68]. Remarkably, the APP gene locus was found on chromosome 21, and the fact that Down syndrome subjects who carry an extra copy of chromosome 21 develop AD at a very early age
Structure and putative functions of the APP
The APP gene is constituted of 18 exons that can be alternatively spliced to create 10 isoforms ranging form 563 to 770 amino acid residues [30]. Peripheral tissues express APP isoforms that contain a serine protease inhibitor insert (KPI) [71], [111], [149] and may regulate blood coagulation factors [130], [143]. Neurons express APP695 isoform that lacks the KPI domain. Two APP gene homologues have also been identified, amyloid precursor-like proteins (APLP-1 and APLP-2) but these have little
APP is proteolytically processed near and within its transmembrane domain
Understanding the proteolytic processing events that take place near and within the APP transmembrane domain may give us clues for designing rational therapies for AD. APP ectodomain can be shed form the membrane by two alternative cleavages: α-secretase cleavage that splits Aβ domain and precludes Aβ formation, and β-secretase cleavage that exposes the amino-terminus of the Aβ peptide (Fig. 3; [41], [132]). Fragments resulting from these two cleavages remain associated with the membrane and
α-Secretase/β-secretase: two alternative routes for APP secretion
α-Secretase cleavage corresponds to the default secretory pathway and predominates in all non-neuronal cells, including mammalian cells [139], [160] and platelets [14], insect cells [10], [90], baculovirus [73], and the yeast [58], [80], [181]. It is usually considered as non-amyloidogenic because it does not produce Aβ; however, its derived product p3 [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36], [37], [38], [39], [40],
γ-Secretase cleavage: the critical step in Aβ generation
Fragments resulting from α- and β-secretase cleavage remain anchored in the membrane and may become degraded or further processed by γ-secretase to form p3 (∼3 kDa peptides derived from α-secretase cleavage) and Aβ (∼4.5 kDa products derived from β-secretase cleavage). The recovery of Aβ peptides from biological fluids and from mammalian cell cultures [133] indicated that γ-secretase cleavage is a normal cellular event. However, this constitutes a rather unusual proteolytic cleavage as it occurs
The PS are directly associated with γ-secretase cleavage
The demonstration, by our group and by others, of a direct molecular interaction between PS and APP [118], [161], [172] suggested PS would play a role in the trafficking or in the cleavage of APP. The finding of an 80% reduction in γ-secretase activity in cells derived from PS 1 (PS1) knockout mice [35] and in cells transfected with PS1 dominant negative mutants [169] proved that γ-secretase, or the γ-secretase pathway, were directly linked with PS1. PS1 knockout experiments have also unveiled
Is there an additional step in the formation of Aβ?
An intriguing question that concerns γ-secretase cleavage remains open. The γ-CTF C-terminal counterpart of Aβ that is expected to be produced by γ-secretase cleavage, has not been characterized. Recent studies have demonstrated the formation of a C-terminal product of APP released by semi-purified γ-secretase preparation in a cell-free system [96], [116]. This fragment has the expected electrophoretic mobility of γ-CTF but no N-terminal sequencing data are provided to confirm its identity. Our
Is γ-secretase cleavage abnormal in AD?
How PS and APP mutations cause abnormal production of longer Aβ isoforms has not been clarified so far. We may propose two hypotheses: either these two peptides are produced by alternative proteases (i.e. PS-associated γ-secretase/degradation mechanism involving endosomal proteases or the proteasome [26], [140]), or they are produced by a same protease acting on alternative substrate conformations. The dual protease hypothesis would be supported by reports that protease inhibitors have slightly
Aβ clearance mechansims
A considerable amount of research activity has been committed to clarifying the cellular mechanisms of Aβ formation and identifying the secretase enzymes. Relatively less effort has been aimed at understanding Aβ metabolism and degradation.
Genetic predisposition to late-onset AD has been linked to apoliprotein E (ApoE) ε4 allele [29]. The three major ApoE alleles commonly found are ε2, ε3, and ε4. Inheritance of at least one ε4 allele decreases considerably the age of AD onset. ApoE was shown
Novel therapeutic strategies for AD
Novel anti-amyloid therapies are currently being investigated. These consist in preventing amyloid formation by interfering directly with the APP secretases (either by inhibiting β- and γ-secretases, or by favoring the α-secretase pathway versus the β-secretase pathway) or in clearing the amyloid peptides by use of defibrillating agents or by immunization (Table 1).
β-Secretase candidate BACE appears to be an ideal target for drug design. Inhibitors have been described that are based on the APP
Acknowledgements
Supported by the National Health and Medical Research Council of Australia (Grant 114150).
References (182)
- et al.
Platelets and DAMI megakaryocytes possess β-secretase-like activity
J. Lab. Clin. Med.
(1999) - et al.
Regulation of amyloid protein precursor (APP) binding to collagen and mapping of the binding sites on APP andcollagen type 1
J. Biol. Chem.
(1996) - et al.
Post-translational processing of β-secretase (BACE) and its ectodomain shedding: the pro- and transmembrane/cytosolic domains affect its cellular activity and amyloid Aβ production
J. Biol. Chem.
(2001) - et al.
Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans
Cell
(2000) - et al.
The amyloid precursor protein of Alzheimer’s disease is released by human platelets
J. Biol. Chem.
(1990) - et al.
A novel zinc(II) binding site modulates the function of the βA4-amyloid protein precursor of Alzheimer’s disease
J. Biol. Chem.
(1993) - et al.
Modulation of Aβ adhesiveness and secretase site cleavage by zinc
J. Biol. Chem.
(1994) - et al.
Evidence that tumor necrosis factor-α converting enzyme is involved in regulated α-secretase cleavage of the Alzheimer amyloid protein precursor
J. Biol. Chem.
(1998) - et al.
Aqueous dissolution of Alzheimer’s disease Aβ-amyloid deposits by biometal depletion
J. Biol. Chem.
(1999) - et al.
Chelation and intercalation: complementary properties in a compound for the treatment of Alzheimer’s disease
J. Struct. Biol.
(2000)
What the evolution of the amyloid protein precursor supergene family tells us about its function
Neurochem. Int.
Expression of the amyloid precursor protein of Alzheimer’s disease on the surface of transfected HeLa cells
Exp. Cell Res.
Alzheimer’s disease amyloid β binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits
J. Biol. Chem.
Presenilins and Alzheimer’s disease: biological functions and pathogenic mechanisms
Prog. Neurobiol.
Degradation of the Alzheimer’s amyloid peptide by endothelin converting enzyme
J. Biol. Chem.
The regions of the Fe65 protein homologous to the phosphotyrosine interaction/phosphotyrosine binding domain of Shc bind the intracellular domain of the Alzheimer’s amyloid precursor protein
J. Biol. Chem.
Amyloid β interactions with chondroitin sulfate-derived monosaccharides
J. Biol. Chem.
Involvement of caspases in proteolytic cleavage of Alzheimer’s amyloid β precursor protein and amyloidogenic Aβ peptide formation
Cell
Alzheimer’s disease and Down’s syndrome: sharing of a unique cerebrovascular amyloid fibril protein
Biochem. Biophys. Res. Commun.
The βA4-amyloid precursor protein binding to copper
FEBS Lett.
Inhibition of β-amyloid formation identifies proteolytic precursors and subcellular site of catabolism
Neuron
Identification of a novel aspartic protease (Asp 2) as β-secretase
Mol. Cell. Neurosci.
Subcellular compartment and molecular subdomain of β-amyloid precursor protein relevant to the Aβ42-promoting effects of Alzheimer mutant presenilin 2
J. Biol. Chem.
Statins and the risk of dementia
Lancet
The carboxyl termini of β-amyloid peptides 1–40 and 1–42 are generated by distinct gamma-secretase activities
J. Biol. Chem.
Isolation of baculovirus-derived secreted and full-length β-amyloid precursor protein
J. Biol. Chem.
Elevated Aβ42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AβPP metabolism
Am. J. Pathol.
Alzheimer’s β-amyloid peptide specifically interacts with and is degraded by insulin-degrading enzyme
FEBS Lett.
Cleavage at the amino and carboxyl termini of Alzheimer’s amyloid β by cathepsin D
J. Biol. Chem.
The type 4 prepilin peptidases comprise a novel family of aspartic acid proteases
J. Biol. Chem.
Alzheimer’s amyloid precursor protein produced by recombinant baculovirus expression. Proteolytic processing and protease inhibitory properties
J. Biol. Chem.
Retention of the Alzheimer’s amyloid precursor fragment c99 in the endoplasmic reticulum prevents formation of amyloid β-peptide
J. Biol. Chem.
The amyloid protein precursor of Alzheimer’s disease is a mediator of the effects of nerve growth factor on neurite outgrowth
Neuron
The β-amyloid precursor protein functions as a cytosolic anchoring site that prevents Fe65 nuclear translocation
J. Biol. Chem.
Uber eine eigenartige Erkrankung der Hirnrinde
Alig. Z. Psychiat.
Unusual phenotypic alteration of β-amyloid precursor protein (βAPP) maturation by a new Val-715→Met βAPP-770 mutation responsible for probable early-onset Alzheimer’s disease
Proc. Natl. Acad. Sci. U.S.A.
Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
Nat. Genet.
Aspartate mutations in presenilin and gamma-secretase inhibitors both impair Notch 1 proteolysis and nuclear translocation with relative preservation of Notch 1 signaling
J. Neurochem.
Evidence for genetic linkage of Alzheimer’s disease to chromosome 10q
Science
Regulation of APP expression, biogenesis and metabolism by extracellular matrix and cytokines
Ann. N Y Acad. Sci.
Expression of active secreted forms of human-amyloid β-protein precursor by recombinant baculovirus-infected insect cells
Proc. Natl. Acad. Sci. U.S.A.
α-2-Macroglobulin is genetically associated with Alzheimer disease
Nat. Genet.
The phosphotyrosine interaction domains of X11 and FE65 bind to distinct sites on the YENPTY motif of amyloid precursor protein
Mol. Cell. Biol.
BACE1 is the major β-secretase for generation of Aβ peptides by neurons
Nat. Neurosci.
Protein phosphorylation regulates secretion of Alzheimer β/A4-amyloid precursor protein
Proc. Natl. Acad. Sci. U.S.A.
The multiple paradoxes of presenilins
J. Neurochem.
A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer’s disease
Nature
Treatment with copper–zinc metal chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer’s disease transgenic mice
Neuron
Purified recombinant insulin-degrading enzyme degrades amyloid β-protein but does not promote its oligomerization
Biochem. J.
Alzheimer’s disease: correlation of the suppression of β-amyloid peptide secretion from cultured cells with inhibition of the chymotrypsin-like activity of the proteasome
J. Neurochem.
Cited by (146)
Brain region-specific myelinogenesis is not directly linked to amyloid-β in APP/PS1 transgenic mice
2023, Experimental NeurologyNeuroprotective effect of tanshinone IIA-incubated mesenchymal stem cells on Aβ <inf>25-35</inf> -induced neuroinflammation
2019, Behavioural Brain ResearchThe genetics of Alzheimer's disease
2019, NPG Neurologie - Psychiatrie - GeriatrieXanthoceraside attenuates amyloid β peptide<inf>1-42</inf>-induced memory impairments by reducing neuroinflammatory responses in mice
2018, European Journal of PharmacologyCitation Excerpt :An extracellular build-up of amyloid beta (Aβ) may be an early pathological marker of AD (Krause and Müller, 2010; Qi et al., 2013; Pláteník et al., 2014). According to the amyloid hypothesis, the neurodegeneration in Alzheimer's disease is caused by abnormal accumulation of Aβ plaques in various areas of brain (Hardy Evin and Weidemann, 2002). Accumulation of Aβ plaques acts as a pathological trigger for a cascade that includes neuronal injury and formation of neurofibrillary tangles via tau protein that leads to neuronal dysfunction and cell death in AD (Kayed et al., 2003).
Alkaloids as Potential Multi-Target Drugs to Treat Alzheimer's Disease
2018, Studies in Natural Products ChemistryCitation Excerpt :Some hypotheses for neurodegeneration come to the fore, among them are the amyloid cascade hypothesis and tau hypothesis. The amyloid cascade hypothesis implies the abnormal accumulation of Aβ plaques, due to excessive aggregation or decreased clearance of Aβ as the primary cause of disease [19,20], whereas the tau hypothesis is based on evidence that tau protein abnormalities initiate the disease cascade [21]. So, MTLs that are able to inhibit cholinesterases and interfere with Aβ aggregation and/or tau protein hyperphosphorylation or neuroinflammation may be useful tools for the treatment of AD.
Agent Orange Herbicidal Toxin-Initiation of Alzheimer-Type Neurodegeneration
2024, Journal of Alzheimer's Disease